In T2D patients, IL-1 receptor antagonist (IL-1RA) production by β-cells is decreased and IL-1β induces inflammation in pancreatic islets through NF-κB activation, which plays a critical role in the development of OA (59). Here, IL1B is linked to type 2 diabetes mellitus.